Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.14) per share. This is unchanged from the same period last year.
Related Posts
Top 5 Consumer Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies. The…
Red White & Bloom Brands Q3 Revenue Falls 7% From Previous Quarter To $18.8M
Red White & Blooms Brands, Inc.